Literature DB >> 20167490

Feasibility study on the treatment of small breast carcinoma using percutaneous US-guided preferential radiofrequency ablation (PRFA).

Hans Wiksell1, Lars Löfgren, Kai-Uwe Schässburger, Helene Grundström, Marina Janicijevic, Ulla Lagerstedt, Karin Leifland, Rolf Nybom, Samuel Rotstein, Ariel Saracco, Inkeri Schultz, Karin Thorneman, Carl Wadström, Lars Westman, Hans Wigzell, Brigitte Wilczek, Gert Auer, Bengt Sandstedt.   

Abstract

The purpose of this study was to determine the safety and efficacy of percutaneous ultrasound (US) guided preferential radiofrequency ablation (PRFA) of unifocal human invasive breast carcinoma with largest radiological diameters of up to 16 mm. Thirty-three patients were enrolled in a study to be treated prior to scheduled partial mastectomy. A needle-shaped treatment electrode, successively developed in two different sizes, was placed into the center of the lesions using ultrasound guidance. A temperature of 85 degrees C was maintained for 10 min. The analysis of the resected specimen was performed using conventional histopathological methods with the aim to determine the size of the lesion as well as the potential viability of tumor cells. Of the 33 patients enrolled 31 were treated. In 26 (84%) patients a complete ablation of the tumor was achieved. Ultrasound guided preferential radiofrequency ablation of small breast carcinoma is feasible and patient friendly. The success rate depends on accurate preoperative diagnostic imaging as well as an exact position of the needle electrode. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20167490     DOI: 10.1016/j.breast.2010.01.016

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  8 in total

Review 1.  Technical success, technique efficacy and complications of minimally-invasive imaging-guided percutaneous ablation procedures of breast cancer: A systematic review and meta-analysis.

Authors:  Giovanni Mauri; Luca Maria Sconfienza; Lorenzo Carlo Pescatori; Maria Paola Fedeli; Marco Alì; Giovanni Di Leo; Francesco Sardanelli
Journal:  Eur Radiol       Date:  2017-01-03       Impact factor: 5.315

2.  Feasibility of percutaneous excision followed by ablation for local control in breast cancer.

Authors:  V Suzanne Klimberg; Cristiano Boneti; Laura L Adkins; Maureen Smith; Eric Siegel; Vladimir Zharov; Scott Ferguson; Ronda Henry-Tillman; Brian Badgwell; Soheila Korourian
Journal:  Ann Surg Oncol       Date:  2011-09-09       Impact factor: 5.344

Review 3.  Percutaneous Management of Breast Cancer: a Systematic Review.

Authors:  Yuqing Dai; Ping Liang; Jie Yu
Journal:  Curr Oncol Rep       Date:  2022-06-14       Impact factor: 5.075

4.  Prevention of tumour cell dissemination in diagnostic needle procedures.

Authors:  H Wiksell; K-U Schässburger; M Janicijevic; K Leifland; L Löfgren; S Rotstein; P-O Sandberg; C Wadström; G Auer
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

Review 5.  Radiofrequency ablation and breast cancer: a review.

Authors:  Tiffany Nguyen; Eleanor Hattery; Vijay P Khatri
Journal:  Gland Surg       Date:  2014-05

6.  Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis.

Authors:  Lin-Yu Xia; Qing-Lin Hu; Wei-Yun Xu
Journal:  Front Oncol       Date:  2021-05-03       Impact factor: 6.244

7.  Breast tissue ablation with irreversible electroporation in rabbits: A safety and feasibility study.

Authors:  Wenlong Zhang; Wanning Wang; Wei Chai; Xiaomei Luo; Jiannan Li; Jian Shi; Liqi Bi; Lizhi Niu
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

8.  A meta-analysis of clinical trials assessing the effect of radiofrequency ablation for breast cancer.

Authors:  Jiayan Chen; Chi Zhang; Fei Li; Liping Xu; Hongcheng Zhu; Shui Wang; Xiaoan Liu; Xiaoming Zha; Qiang Ding; Lijun Ling; Wenbin Zhou; Xinchen Sun
Journal:  Onco Targets Ther       Date:  2016-03-23       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.